| Aug 20 |
Galapagos receives transparency notification from FMR LLC
|
| Aug 12 |
ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload
|
| Aug 2 |
Galapagos pauses enrollment in Phase 1/2 study for GLPG5301
|
| Aug 2 |
Galapagos downgraded at Raymond James on lack of business development
|
| Aug 2 |
Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
Galapagos, BridGene expand agreement to develop small molecule oncology asset
|
| Aug 1 |
Galapagos GAAP EPS of €1.51, revenue of €140.3M
|
| Aug 1 |
Galapagos reports half-year 2024 financial results and provides second quarter business update
|
| Aug 1 |
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
|
| Jun 14 |
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
|
